Long Term Streptomycin toxicity in the treatment of Buruli Ulcer: Follow-up of participants in the BURULICO drug trial

Sandor Klis, Ymkje Stienstra, Richard O Phillips, Kabiru M. Abass, Wilson Tuah, Tjip S. van der Werf.

PLoS Negl Trop Dis. 2014 Mar 13;8(3):e2739.
Abstract

Background: Buruli Ulcer (BU) is a tropical infectious skin disease that is currently treated with 8 weeks of intramuscular streptomycin and oral rifampicin. As prolonged streptomycin administration can cause both oto- and nephrotoxicity, we evaluated its long term toxicity by following-up former BU patients that had received either 4 or 8 weeks of streptomycin in addition to other drugs between 2006 and 2008, in the context of a randomized controlled trial.

Methods: Former patients were retrieved in 2012, and oto- and nephrotoxicity were determined by audiometry and serum creatinine levels. Data were compared with baseline and 2, 4, 6, and 8 week measurements during the drug trial.

Results: Of the total of 151 former patients, 127 (84%) were retrieved. Ototoxicity was present in 29% of adults and 25% of children. Adults in the 8 week streptomycin group had significantly lower hearing thresholds in all frequencies at long term follow-up, and these differences were most prominent in the high frequencies. In children, no differences between the two treatment arms were found. Nephrotoxicity that had been detected in 14% of adults and in 13% of children during treatment, was present in only 2.4% of patients at long term follow-up.

Conclusions: Prolonged streptomycin administration in the adult study subjects caused significant persistent hearing loss, especially in the high frequency range. Nephrotoxicity was also present in both adults and children but appeared to be transient.
Chapter 2

Introduction

Buruli ulcer (BU) is a Neglected Tropical Disease caused by infection with *Mycobacterium ulcerans*. Necrotic skin lesions characterize the disease, often with typical undermined edges. Treatment delay may result in disfigurement and functional limitations (1). Though isolated cases or small outbreaks have been reported in over 30 countries, the disease is mainly found in endemic areas in rural West- and Central-Africa, with around 6,000 cases occurring annually (2–4).

Over the past decade the main mode of treatment has shifted from surgery to antimicrobial therapy. Several antibiotic regimens have been proposed and studied, and the current regimen advised by the World Health Organization consists of 8 weeks of oral rifampicin and intramuscular streptomycin (5–8). Although surgery can be problematic in under-resourced developing countries due to high costs and low availability, prolonged streptomycin administration has complications of its own. These complications are partly related to the parenteral mode of administration of streptomycin, but also to its intrinsic toxicity, notably, ototoxicity and nephrotoxicity (9).

Streptomycin induced ototoxicity encompasses damage to both the cochlea and vestibulum (10), although the effects of vestibular damage can to some extent be compensated for by the brain, and so are clinically less prominent (11). The damage is caused by reactive oxygen species that are formed by a redox-active complex of parts of the aminoglycoside and biologically available iron ions (12). The most frequently reported manifestations of ototoxicity are high-frequency sensorineural hearing loss, and vestibular dysfunction resulting in disequilibrium and loss of the vestibular ocular-reflex (12). These side-effects are often transient, but chronic effects, especially hearing loss, have also been reported. The wide range in incidence varies between 5% and 25%, depending on the specific aminoglycoside drug, patient group (older age groups are probably more vulnerable), and definition of ototoxicity including the method of detection (13, 14). The occurrence of ototoxicity does not appear to be related to the individual dosages or the frequency of administration per se, but rather to the cumulative dose, and the age of the patient (15). Also, there appears to be a modest genetic susceptibility, caused by a point mutation in mitochondrial DNA (16).

The nephrotoxic effects of streptomycin are most prominent in the proximal tubule, and transient nephropathy, manifested by a slow rise in serum creatinine and a decreased glomerular filtration rate, is observed in 10–20% of therapeutic courses (17). Unlike aminoglycoside-induced ototoxicity, long-term kidney damage is uncommon. It has long been hypothesized that aminoglycoside-induced nephrotoxicity would lead to increased serum concentrations of the drug, resulting in ototoxicity, or that some other link between aminoglycoside induced ototoxicity and nephrotoxicity existed. Several studies have however been unable to demonstrate such a relationship, and it is believed that the two are largely independent (15, 18, 19).
Long Term Streptomycin toxicity in the treatment of Buruli Ulcer: Follow-up of participants in the BURULICO drug trial

With a total cumulative dose of up to 56 g (15 mg/kg daily with a 1 g daily maximum, 56 doses), the amount of streptomycin that is administered to treat BU is higher than in the treatment of brucellosis, endocarditis, and urinary tract infections, but similar to the treatment of *Mycobacterium avium* complex and second line treatment for tuberculosis. However, no data exist on the long-term toxicity of the currently recommended regimen of antimicrobial therapy in BU. Therefore, we chose to study former BU patients that participated earlier in a randomized controlled trial conducted between 2006 and 2008 (20). In that trial patients were randomized to receive either 8 or 4 weeks of streptomycin, allowing a direct comparison between the two groups in terms of long-term streptomycin toxicity.

**Materials and Methods**

**Ethics**

The study protocol was approved by the Committee on Human Research, Publication, and Ethics of the Kwame Nkrumah University of Science and Technology and the Komfo Anokye Teaching Hospital, Kumasi (reference number CHRPE/AP/133/12). Written and verbal informed consent or assent was obtained from all participants aged ≥ 12 years, and consent from parents, or legal representatives of participants aged ≤ 18 years.

**Sample size and patient recruitment**

We retrieved our study subjects among individuals that had earlier participated in the Burulico trial, conducted between 2006 and 2009 in Ghana, registered with number NCT00321178 at clinicaltrials.gov. For that trial, patients aged 5 years or older, clinically diagnosed with early (duration < 6 months), limited (cross-sectional diameter < 10 cm) *M. ulcerans* infection were included, and randomized to receive either 8 weeks of streptomycin at 15mg/kg daily (max 1000 mg daily) and 8 weeks of rifampicin at 10mg/kg daily (max 600 mg daily), or 4 weeks of streptomycin and rifampicin, followed by 4 weeks of rifampicin and clarithromycin at 7.5mg/kg daily. Pregnancy, drug intolerance, and renal, hepatic, and acoustic impairment were among the exclusion criteria, and co-medication with drugs other than the study drugs occurred in less than 5% of patients, and mainly consisted of NSAIDs. Patients had a median age of 12 and 30% were male. Patient characteristics are described in more detail in Nienhuis et al. (20).

For the present follow-up study, participants were retrieved between June and November 2012 by visiting their last known village or through telephone contact if avail-
able. If the former patient was no longer living at the last known village, neighbors, relatives, and community leaders were asked for additional information. When a former patient was located, he or she was informed about the study, given time to consider participation, and was asked for consent.

Procedures

Audiometry was performed in a quiet room in one of the two study hospitals of the BURULICO drug trial with portable Interacoustics AS208 audiometers, with circumaural earphones with noise reducing Peltor mute cushions. The audiometers were calibrated to ISO64, with biological calibration performed at frequent intervals. As soundproof rooms were not available at the study sites, ambient noise (AN) levels were measured with a voltcraft SL-100 ambient noise meter in dBA filter weighting during each audiometry session.

The person performing the follow-up audiometry was blinded to the treatment allocation during the Burulico study, and was therefore unaware of earlier streptomycin treatment duration. Both ears were tested, the right ear first. Frequencies were tested in the following order: 1, 2, 4, 6, 8, 0.5 and 0.25 kHz. Testing started with presenting a loud tone. Then the intensity was decreased in steps of 5 dB until the tone was not heard anymore. The last tone still heard was the level of audibility of the first test run. Then the intensity was increased with 10 dB before being decreased again in steps of 5 dB, until the tone was no longer heard (the second test run). If the results of the two test runs were not identical, the process was repeated until two identical levels of audibility were found. This level was considered the hearing threshold. The same procedure was followed during the drug trial, and so, audiograms were available for baseline, after 8 weeks of treatment, and at long-term follow-up. In addition to audiometry, each subject was asked at follow-up about complaints of hearing loss and dizziness after completion of treatment.

To detect late nephrotoxic effects of the streptomycin administration 4–6 years earlier, serum creatinine was measured in a sample of venous blood (approximately 2ml) at the same laboratory, where serum creatinine was measured during the drug trial, using the same analytic technique. The results were compared with the measurements at baseline, after 2, 4, 6, and 8 weeks of treatment during the BURULICO study. Patients with suspected long-term nephrotoxicity were referred to the hospital for further management.

The total cumulative dose of streptomycin administered was estimated to be 56 times the daily dose. Individual records of compliance were not available, but during the drug trial, streptomycin administration was only performed in participating hospitals and health centers and was recorded on tally sheets with compliance approaching 100%.
Data analysis

As aminoglycoside toxicity is reported to occur less frequently in children (21, 22), we analyzed the results separately for those ≤ 16 and > 16 years of age at the time of receiving streptomycin treatment during the Burulico trial. For each frequency, the mean of measurement results of audiometry of both ears was recorded. As the distribution of hearing thresholds is usually skewed to the left, differences between the two treatment arms were assessed with nonparametric Mann-Whitney-U tests. According to the criteria of the American Speech-Language-Hearing Association (23), an increased threshold of 20dB at any one frequency or an increase of 15 dB at two consecutive frequencies was classified as hearing loss. Nephrotoxicity was defined as a rise in serum creatinine at two consecutive assessments during treatment compared to baseline of ≥ 44 μmol/L (0.5mg/dL) or 50% (17, 24). As serum creatinine levels increase with age and body weight, especially muscle mass, it was not possible to make a meaningful direct comparison between the serum creatinine concentrations in the present study with those obtained 4–6 years earlier during the drug trial. Instead, a decrease of the estimated Glomerular Filtration Rate (eGFR) of > 25% in this follow-up study compared to baseline was defined as long term nephrotoxicity (25). In adults, the eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (26), as this was earlier shown to be superior to other equations in a Ghanaian population (27). In children the eGFR was computed using the revised Schwartz formula (28).

Results

Patient population and retrieval

127 individuals (84%) of the 151 former participants of the Burulico trial were retrieved for follow up. Although the trial had taken place in the Ashanti region of Ghana, many former patients were not ethnically Ashanti, and had moved away from the study site, and patients were retrieved in 9 of Ghanas 11 regions, including the three Northern regions more than 700 kilometers and approximately 10 hours by road from the original study site. 68% of the retrieved former patients were female, and the median age at follow-up was 18 years. 68% of our study participants had been 16 or younger at the time they received treatment during the Burulico trial. Of the 24 former patients not retrieved, 4 were already lost to follow-up during the Burulico trial, 3 had moved abroad, 2 had deceased, and the fate of the remaining 15 was unknown. The patients that were lost to follow-up did not differ significantly from the patients that were retrieved in terms of baseline and 8 week audiometry and serum creatinine, age, sex or treatment arm. The median duration
between drug administration and follow-up was 5 years. Overall, the patients reported to be doing well. 28% reported to have experienced another disease since their BU was cured, with most patients reporting malaria, headache, and stomach ache. One retrieved patient was HIV-positive. 3 patients reported currently taking analgesics, and 2 patients reported currently taking anti-hypertensives.

Table 1. Univariate associations with long term ototoxicity. All \( P \) values are 1-tailed except for sex.

| Adults \((N=41)\) | Ototoxicity | \(P\) value |
|------------------|-------------|-------------|
|                  | Yes     | No         |            |
| Treatment arm    |          |            |            |
| 8 weeks streptomycin | 40%   | 60%        | .114       |
| 4 weeks streptomycin | 23%    | 77%        | .150       |
| Age during treatment (SD) | 32(17) | 27(11)    |            |
| Seks             |          |            |            |
| Male             | 57%     | 43%        | .101       |
| Female           | 26%     | 74%        |            |
| Total grams of streptomycin (SD) | 40(15) | 34(13)    | .090       |
| Complaints of hearing loss | Yes   | No         |            |
| Yes              | 25%     | 75%        | .393       |
| No               | 32%     | 68%        |            |

| Children \((N=86)\) | Ototoxicity | \(P\) value |
|---------------------|-------------|-------------|
|                     | Yes     | No         |            |
| Treatment arm       |          |            |            |
| 8 weeks streptomycin | 26%   | 74%        | .414       |
| 4 weeks streptomycin | 28%    | 72%        | .274       |
| Age during treatment (SD) | 10(3)  | 9(3)       |            |
| Seks                |          |            |            |
| Male                | 24%     | 76%        | .505       |
| Female              | 29%     | 71%        |            |
| Total grams of streptomycin (SD) | 23(12) | 21(9)    | .220       |
| Complaints of hearing loss | Yes   | No         |            |
| Yes                 | 40%     | 60%        | .164       |
| No                  | 25%     | 75%        |            |
Ototoxicity

29% of adults, and 25% of children were classified as having hearing loss compared to baseline audiometry after 8 weeks of treatment, and 31% of adults, and 27% of children were classified as having hearing loss at long term follow-up compared to baseline audiometry. The average hearing thresholds at long-term follow up for both treatment arms for adults are shown in Figure 1, and for children in Figure 2. At baseline, no differences between the two treatment arms existed in any of the frequencies, and after 8 weeks of treatment, the pattern of differences was similar to long-term follow up, but less pronounced. For both adults and children, univariate associations between long term ototoxicity and treatment arm, age, sex, total cumulative dose of streptomycin and complaints of hearing loss were determined. The results are shown in table 1. The average (SD) level of ambient noise (AN) was 45.6 (6.5) dB.

Table 2. Univariate associations with nephrotoxicity during treatment. All P values are 1-tailed except for sex.

| Adults (N=41) | Nephrotoxicity |   |   |
|---------------|----------------|---|---|
|               | Yes | No | P value |
| Treatment arm |     |    |         |
| 8 weeks streptomycin | 20% | 80% | .157 |
| 4 weeks streptomycin | 9% | 91% |
| Age during treatment (SD) | 29(10) | 29(13) | .470 |
| Sex |     |    |         |
| Male | 29% | 71% |
| Female | 11% | 89% | .237 |
| Total grams of streptomycin (SD) | 40(11) | 35(15) | .178 |

| Children (N=86) | Nephrotoxicity |   |   |
|-----------------|----------------|---|---|
|                 | Yes | No | P value |
| Treatment arm   |     |    |         |
| 8 weeks streptomycin | 20% | 80% | .024 |
| 4 weeks streptomycin | 5% | 95% |
| Age during treatment (SD) | 10(3) | 9(3) | .254 |
| Sex |     |    |         |
| Male | 9% | 91% |
| Female | 16% | 84% | .356 |
| Total grams of streptomycin (SD) | 26(7) | 21(10) | .041 |
From self report, 10% of adults reported experiencing hearing loss (5% in the 8 week streptomycin group vs 16% in the 4 week streptomycin group; $p > 0.3$ by $X^2$) and 12% of children reported experiencing hearing loss (9% in the 8 week streptomycin group vs 15% in the 4 week streptomycin group; $p > 0.3$ by $X^2$) after treatment was completed. 10% of adults reported experiencing dizziness (5% in the 8 week streptomycin group vs 16% in the 4 week streptomycin group; $p > 0.3$ by $X^2$) and 12% of children reported experiencing hearing loss (9% in the 8 week streptomycin group vs 15% in the 4 week streptomycin group; $p > 0.3$ by $X^2$) after treatment was completed. However, there appeared to be no association between audiometrically classified and self-reported hearing loss, as 14% of the patients that were audiometrically classified as having hearing loss at long term follow-up also complained of hearing loss vs 9% of patients that were not audiometrically classified as having hearing loss ($p > 0.3$ by $X^2$).

Nephrotoxicity

During treatment, 14% of adults, and 13% of children were classified as having nephrotoxicity. At long term follow-up 1 adult (2.4%) and 2 children (2.4%) were classified as having long-term nephrotoxicity. All 3 of these patients had received streptomycin for 8 weeks ($p < 0.1$ by $X^2$), but only 1 was also classified as having nephrotoxicity during treatment. The average serum creatinine concentrations for both treatment arms for adults are shown in Figure 3, and for children in Figure 4. For both adults and children, univariate associations between nephrotoxicity and treatment arm, age, weight, sex, and total cumulative dose of streptomycin were determined. The results are shown in table 2.
Figure 1. Mean hearing thresholds of adults (16 or older at the time of treatment) in dB averaged over both ears. The shaded area represents the area used in understanding human speech (Pascoe, 1980)(37). SR8 = participants in the 8 week Streptomycin / Rifampicin group. SR4/CR4 = participants in the 4 week Streptomycin / Rifampicin plus 4 week Clarithromycin / Rifampicin group. The Differences between the two groups were tested with the Mann-Whitney U test, 1-tailed. * = p < 0.05, ** = p < 0.001.
Figure 2. Mean hearing thresholds of children (under 16 at the time of treatment) in dB averaged over both ears. The shaded area represents the area used in understanding human speech (Pascoe, 1980)(37). SR8 = participants in the 8 week Streptomycin / Rifampicin group. SR4/CR4 = participants in the 4 week Streptomycin / Rifampicin plus 4 week Clarithromycin / Rifampicin group. The Differences between the two groups were tested with the Mann-Whitney U test, all differences were ns.
Figure 3. Mean (SD) serum creatinine concentrations of adults (16 or older at the time of treatment), measured at baseline, after 8 weeks of treatment and at long term follow-up. SR8 = participants in the 8 week Streptomycin / Rifampicin group. SR4/CR4 = participants in the 4 week Streptomycin / Rifampicin plus 4 week Clarithromycin / Rifampicin group. The differences between the two groups at baseline were tested with the students t-test. The differences between the two groups after 8 weeks of treatment and at long-term follow up were tested with an ANCOVA, controlling for serum creatinine concentration at baseline and age. * = p < 0.05, others ns (N=41).
Discussion

In this study we followed-up individuals that were randomly assigned to either 4 or 8 weeks of streptomycin injections 4 to 6 years earlier, and that had similar results in audiometry at baseline. This provided a unique model to compare long-term toxicity incurred by doubling the cumulative dosage of streptomycin. In adults, we found an important and clinically relevant increase in hearing loss in the high frequencies in individuals that had received 8 weeks of streptomycin, in comparison to those that had received only 4 weeks of this aminoglycoside. In children, no differences between the two treatment arms were detectable.

Although macrolides, especially, azithromycin have also been connected to hearing loss (29), the ototoxicity associated with prolonged streptomycin use was significantly more pronounced than in individuals that had received clarithromycin instead.

The ototoxic effects of prolonged duration of streptomycin therapy appeared to differ between adults and children. To our knowledge, no studies have evaluated the ototoxicity of an aminoglycoside in a study population consisting of both children and adults.
suffering from the same illness, exposed to the same treatment schedule. Low levels of ototoxicity in children have been reported before (21, 22), but the exact mechanisms for this interaction with age are not well understood (21).

The incidence of hearing loss in our study was slightly higher than in earlier reports, which may be due to the fact that we used the formal ASHA criteria that are designed to detect early changes, so as to avoid more severe damage with ongoing aminoglycoside administration.

In children, there was only a weak relationship between hearing loss detected by audiometry and complaints of hearing loss by the patient, and in adults there was no relationship at all. Audiometric and subjective ototoxicity often correlate poorly (15, 30, 31), because audiometric toxicity is usually – as in our study – present in the high frequencies. High frequency hearing loss does not affect primary speech hearing, but rather affects the ability to follow group conversations, and causes people to hear the wrong words without noticing it (32). This may explain why many clinicians are not very concerned about ototoxicity in the treatment of BU, as their patients usually do not report hearing loss spontaneously.

In our study, nephrotoxicity was present in both children and adults, occurred more often in the 8 week streptomycin group and appeared to be related to the total cumulative dose of streptomycin. However, long term nephrotoxicity was only detected in 3 study subjects. The occurrence of both transient and long-term streptomycin nephrotoxicity in our study might be a low estimate for the population at risk in general, as BU is a local infection, usually without systemic involvement, and most patients were young and did not have any significant comorbidities, medical history or co-medication, contrary to other patient categories that are administered aminoglycosides, e.g. ICU patients or those with cystic fibrosis. In addition, streptomycin was administered once daily, which is known to reduce the incidence of nephrotoxicity (33).

Our study had several limitations. First, after an intensive search, we only retrieved 127 (84%) of the population that we intended to study. Of the 24 subjects that were lost to follow-up, we could not detect features that might have introduced bias, but we cannot completely rule out that some bias was introduced. Next, although the group that was earlier exposed to 4 weeks of streptomycin had (near) normal audiograms, we did not attempt to enroll a matched control group that had not had streptomycin injections. Also, variability between measurements is likely to be higher than desirable, due to high levels of AN, although average levels of AN were only slightly higher compared to accepted bedside testing levels in the USA (34),(35). This implies that the absolute numbers of hearing loss should be interpreted with caution, but as AN levels were similar for all measurements, it is not likely to have influenced the differences found between the two treatment arms.
The strength of our findings is that we could detect a difference between groups that appeared well matched. With known baseline characteristics, with a well-documented increased exposure to streptomycin, we conclude that prolonged streptomycin administration in the adult study subjects caused significant hearing loss, especially in the high frequency range. In addition, we obtained ototoxicity data from a patient sample that included both adults and children suffering from the same illness and receiving the same treatment, with differential effects in terms of toxicity.

Our study results support ongoing attempts to try replacing injected streptomycin by an alternative, e.g. clarithromycin. Currently a trial to compare standard care (streptomycin plus rifampicin) with oral treatment consisting of clarithromycin in extended release formulation combined with rifampicin is ongoing (36).

We conclude that streptomycin with cumulative dosages, especially in patients aged 16 or older should be given with caution, especially in individuals with concurrent risks for renal dysfunction or hearing loss.

**Declarations**

SK was supported by an MD/PhD grant of the Junior Scientific Masterclass, Groningen University. YS was supported by a VENI grant from the Netherlands Organisation for Scientific Research. The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter discussed in this manuscript. The study protocol was approved by the Committee on Human Research, Publication, and Ethics of the Kwame Nkrumah University of Science and Technology and the Komfo Anokye Teaching Hospital, Kumasi (reference number CHRPE/AP/133/12).
References

1. Stienstra Y, van Roest MH, van Wezel MJ, Wiersma IC, Hospers IC, Dijkstra PU, et al. Factors associated with functional limitations and subsequent employment or schooling in buruli ulcer patients. Trop Med Int Health. 2005 Dec;10(12):1251–7.
2. van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, Fleischer B, et al. Mycobacterium ulcerans disease. Bull World Health Organ. 2005 Oct;83(10):785–91.
3. Wansbrough-Jones M, Phillips R. Buruli ulcer: Emerging from obscurity. Lancet. 2006 Jun 3;367(9525):1849–58.
4. WHO fact sheet on buruli ulcer [Internet]; 2012. Available from: http://www.who.int/mediacentre/factsheets/fs199/en/.
5. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH. Activities of rifampin, rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis. 2011 Jan 4;5(1):e933.
6. Billal DS. Antimicrobial drugs for buruli ulcer. Lancet. 2010 May 29;375(9729):1873; author reply 1873–4.
7. Kibadi K, Boelaert M, Fraga AG, Kayinua M, Longatto-Filo A, Minuku JB, et al. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be buruli ulcer (mycobacterium ulcerans disease). PLoS Negl Trop Dis. 2010 Jul 6;4(7):e736.
8. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, et al. Clinical efficacy of combination of rifampin and streptomycin for treatment of mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2010 Sep;54(9):3678–85.
9. Johnson PDR. Streptomycin. In: Grayson LM, editor. Kucers’ The Use of Antibiotics. 6th ed. London, United Kingdom: Hodder Arnold / ASM Press; 2012.
10. Mattie H, Craig WA, Pechere JC. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989 Sep;24(3):281–93.
11. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119–26.
12. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology. 2008 Jul 30;249(2–3):91–6.
13. Rizzi MD, Hirose K. Aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg. 2007 Oct;15(5):352–7.
14. Xie J, Talaska AE, Schacht J. New developments in aminoglycoside therapy and ototoxicity. Hear Res. 2011 Nov;281(1–2):28–37.
15. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huit GA, et al. Aminoglycoside toxicity: Daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004 Jun 1;38(11):1538–44.
16. Fischel-Ghodsian N. Genetic factors in aminoglycoside toxicity. Ann N Y Acad Sci. 1999 Nov 28;884:99–109.
17. Bertino JS,Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993 Jan;167(1):173–9.
18. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002 Jul;6(7):622–7.
19. Smith CR, Lipsky JJ, Lietman PS. Relationship between aminoglycoside-induced nephrotoxicity and auditory toxicity. Antimicrob Agents Chemother. 1979 Jun;15(6):780–2.
20. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, et al. Antimicrobial treatment for early, limited mycobacterium ulcerans infection: A randomised controlled trial. Lancet. 2010 Feb 20;375(9715):664–72.
21. McCracken GH, Jr. Aminoglycoside toxicity in infants and children. Am J Med. 1986 Jun 30;80(6B):172–8.
22. Best EJ, Gazarian M, Cohn R, Wilkinson M, Palasanthiran P. Once-daily gentamicin in infants and children: A prospective cohort study evaluating safety and the role of therapeutic drug monitoring in minimizing toxicity. Pediatr Infect Dis J. 2011 Oct;30(10):827–32.
23. ASHA. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;36(Suppl 12):11–9.
24. Smith CR, Lipsky JJ, Laskin OL, Hellmann DB, Mellits ED, Longstreth J, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980 May 15;302(20):1106–9.
25. Oliveira JF, Silva CA, Barbieri CD, Oliveira GM, Zanetta DM, Burdumann EA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009 Jul;53(7):2887–91.
26. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF,3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604–12.
27. Eastwood JB, Kerry SM, Plange-Rhule J, Micah FB, Antwi S, Boa FG, et al. Assessment of GFR by four methods in adults in ashanti, ghana: The need for an eGFR equation for lean african populations. Nephrol Dial Transplant. 2010 Jul;25(7):2178–87.
28. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629–37.
29. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA, Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2004 Apr;351(1):381–5.
30. Hashimoto H, Nomura K, Yano E. Psychosomatic status affects the relationship between subjective hearing difficulties and the results of audiometry. J Clin Epidemiol. 2004 Apr;57(4):381–5.
31. Ross JA, Macdiarmid Ji, Dick FD, Watt SJ. Hearing symptoms and audiometry in professional divers and offshore workers. Occup Med (Lond). 2010 Jan;60(1):36–42.
32. Hogan CA, Turner CW. High-frequency audibility: Benefits for hearing-impaired listeners. J Acoust Soc Am. 1998 Jul;104(1):432–41.
33. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995 Mar;39(3):650–5.
34. ASHA. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;36(Suppl 12):11–9.
35. Valente M, Potts LG, Valente LM, French-St. George M, Goebel J. High-frequency thresholds: Sound suite versus hospital room. J Am Acad Audiol. 1992;3(17):287–94.

36. WHO drug study for buruli ulcer—comparison of SR8 and CR8. in: ClinicalTrials.gov. NLM identifier: NCT01659437 [Internet]; 2013. Available from: http://clinicaltrials.gov/show/NCT01659437.

37. Pascoe DP. Clinical implications of nonverbal methods of hearing aid selection and fitting. Sem Speech Lang Hear. 1980;1(3):217–29.